Long-term outcome of the unrestricted use of everolimus-eluting stents compared to sirolimus-eluting stents and paclitaxel-eluting stents in diabetic patients: The Bern-Rotterdam diabetes cohort study

International Journal of Cardiology

Volumn 170, Issue 1, 2013, Pages 36-42

  Simsek, C ^a   Raber L ^a,b   Magro, M ^a   Boersma, E ^a   Onuma, Y ^a   Stefanini, G G ^b   Zanchin, T ^b   Kalesan, B ^c   Wenaweser, P ^b   Juni P ^b   Van Geuns, R J ^a   Van Domburg, R T ^a   Windecker, S ^b   Serruys, P W J C ^a  

^a ERASMUS MEDICAL CENTER   (Netherlands)

^b UNIVERSITY OF BERN   (Switzerland)

^c UNIVERSITY OF BERN   (Switzerland)

Author keywords

Diabetes mellitus; Everolimus eluting stent; Paclitaxel eluting stent; Percutaneous coronary intervention; Sirolimus eluting stent

Indexed keywords

EVEROLIMUS; PACLITAXEL; RAPAMYCIN;

ADULT; AGED; ARTICLE; CARDIOVASCULAR MORTALITY; COHORT ANALYSIS; COMPARATIVE EFFECTIVENESS; CONTROLLED STUDY; DIABETES MELLITUS; DIABETIC PATIENT; DRUG ELUTING STENT; FEMALE; FOLLOW UP; HEART INFARCTION; HEART MUSCLE REVASCULARIZATION; HIGH RISK POPULATION; HUMAN; INTERMETHOD COMPARISON; MAJOR CLINICAL STUDY; MALE; OUTCOME ASSESSMENT; PATIENT SAFETY; PERCUTANEOUS CORONARY INTERVENTION; PRIORITY JOURNAL; RISK ASSESSMENT; RISK FACTOR; STENT THROMBOSIS;

ACADEMIC RESEARCH CONSORTIUM; ADJUSTED HAZARD RATIO; AHR; ARC; BARE-METAL STENTS; BMS; CI; CONFIDENCE INTERVAL; DES; DIABETES MELLITUS; DM; DRUG-ELUTING STENTS; ECG; EES; ELECTROCARDIOGRAPHY; EVEROLIMUS-ELUTING STENT; EVEROLIMUS-ELUTING STENTS; INTER QUARTILE RANGE; IQR; MACE; MAJOR ADVERSE CARDIAC EVENTS; MI; MYOCARDIAL INFARCTION; PACLITAXEL-ELUTING STENT; PACLITAXEL-ELUTING STENTS; PCI; PERCUTANEOUS CORONARY INTERVENTION; PES; RAPAMYCIN-ELUTING STENT EVALUATED AT ROTTERDAM CARDIOLOGY HOSPITAL; RESEARCH; SD; SES; SIROLIMUS-ELUTING STENT; SIROLIMUS-ELUTING STENTS; ST; STANDARD DEVIATION; STENT THROMBOSIS; T-SEARCH; TARGET-LESION REVASCULARIZATION; TARGET-VESSEL REVASCULARIZATION; TAXUS-STENT EVALUATED AT ROTTERDAM CARDIOLOGY HOSPITAL; TLR; TVR; X-SEARCH; XIENCE-STENT EVALUATED AT ROTTERDAM CARDIOLOGY HOSPITAL;

AGED; COHORT STUDIES; DIABETES MELLITUS; DRUG-ELUTING STENTS; FEMALE; FOLLOW-UP STUDIES; HUMANS; MALE; MIDDLE AGED; NETHERLANDS; PACLITAXEL; SIROLIMUS; TIME FACTORS; TREATMENT OUTCOME;

EID: 84888012442     PISSN: 01675273     EISSN: 18741754     Source Type: Journal    
DOI: 10.1016/j.ijcard.2013.10.006     Document Type: Article

References (19)

1. A.H. Mokdad, E.S. Ford, and B.A. Bowman Prevalence of obesity, and obesity-related health risk factors, 2001 JAMA 289 2003 76 79
2. D.E. Cutlip, A.G. Chhabra, and D.S. Baim Beyond restenosis: five-year clinical outcomes from second-generation coronary stent trials Circulation 110 2004 1226 1230
3. T.T. Lee, L. Feinberg, and D.S. Baim Effect of diabetes mellitus on five-year clinical outcomes after single-vessel coronary stenting (a pooled analysis of coronary stent clinical trials) Am J Cardiol 98 2006 718 721
4. C. Berry, J.C. Tardif, and M.G. Bourassa Coronary heart disease in patients with diabetes II: recent advances in coronary revascularization J Am Coll Cardiol 49 2007 643 656
5. D. Aronson, Z. Bloomgarden, and E.J. Rayfield Potential mechanisms promoting restenosis in diabetic patients J Am Coll Cardiol 27 1996 528 535
6. I. Moussa, M.B. Leon, and D.S. Baim Impact of sirolimus-eluting stents on outcome in diabetic patients: a SIRIUS (SIRoLImUS-coated Bx Velocity balloon-expandable stent in the treatment of patients with de novo coronary artery lesions) substudy Circulation 109 19 2004 2273 2278
7. J.B. Hermiller, A. Raizner, and L. Cannon Outcomes with the polymer-based paclitaxel-eluting TAXUS stent in patients with diabetes mellitus: the TAXUS-IV trial J Am Coll Cardiol 45 8 2005 1172 1179
8. M. Sabate, P. Jimenez-Quevedo, and D.J. Angiolillo Randomized comparison of sirolimus-eluting stent versus standard stent for percutaneous coronary revascularization in diabetic patients: the diabetes and sirolimus-eluting stent (DIABETES) trial Circulation 112 2005 2175 2183
9. P. Ortolani, M. Balducelli, and P. Marzaroli Two-year clinical outcomes with drug-eluting stents for diabetic patients with de novo coronary lesions: results from a real-world multicenter registry Circulation 117 7 2008 923 930
10. Y. Onuma, N. Kukreja, and N. Piazza Interventional Cardiologists of the Thoraxcenter (2000-2007). The everolimus-eluting stent in real-world patients: 6-month follow-up of the X-SEARCH (XIENCE V Stent Evaluated at Rotterdam Cardiology Hospital) registry J Am Coll Cardiol 54 3 2009 269 276
11. G.W. Stone, E. Kedhi, and D.J. Kereiakes Differential clinical responses to everolimus-eluting and paclitaxel-eluting coronary stents in patients with and without diabetes mellitus Circulation 124 2011 893 900
12. W.J. Kim, S.W. Lee, and S.W. Park Randomized comparison of everolimus-eluting stent versus sirolimus-eluting stent implantation for de novo coronary artery disease in patients with diabetes mellitus (ESSENCE-DIABETES): results from the ESSENCE-DIABETES trial Circulation 124 8 2011 886 892
13. J. Daemen, P. Wenaweser, and K. Tsuchida Early and late coronary stent thrombosis of sirolimus-eluting and paclitaxel-eluting stents in routine clinical practice: data from a large two-institutional cohort study Lancet 369 9562 2007 667 678
14. D.E. Cutlip, S. Windecker, and R. Mehran Circulation 115 17 2007 2344 2351
15. L. Raber, M. Magro, and G.G. Stefanini Very late coronary stent thrombosis of newer generation everolimus-eluting stents compared with early generation drug-eluting stent: a prospective cohort study Circulation 125 9 2012 1110 1121
16. G.W. Stone, M. Midei, and M. Newman Comparison of an everolimus-eluting stent and a paclitaxel-eluting stent in patients with coronary artery disease: a randomized trial JAMA 299 16 2008 1903 1913
17. Presentation TCT, 27th of September 2010, Washington, United Stated of America. Kim HS. Efficacy of Xience/Promus versus Cypher to reduce late loss in stent.
18. G. Sarno, B. Lagerqvist, and O. Frobert Lower risk of stent thrombosis and restenosis with unrestricted use of "new-generation" drug-eluting stents: a report from the nationwide Swedish Coronary Angiography and Angioplasty Registry (SCAAR) Eur Heart J 33 5 2012 606 613
19. T. Palmerini, G. Biondi-Zoccai, and D. Della Riva Stent thrombosis with drug-eluting and bare-metal stents: evidence from a comprehensive network meta-analysis Lancet 379 9824 2012 1393 1402